Skip to main content
. 2019 Mar 22;11(3):403. doi: 10.3390/cancers11030403

Figure 2.

Figure 2

Endoxifen and tamoxifen AUC0–24h per individual patient per treatment phase: (a) Tamoxifen AUC0–24h per individual patients per treatment phase. (b) endoxifen AUC0–24h per individual patients per treatment phase. Patients with an intermediate CYP2D6 metabolism (IM) were colored blue. Patients with an extensive CYP2D6 metabolism (EM) were colored black. Poor CYP2D6 metabolizers (PM) and ultra-rapid CYP2D6 metabolizers (UR) were colored green and red, respectively; *: decrease in AUC0–24h >25%; a total of four patients showed a >25% decrease in endoxifen AUC0–24h and three patients in tamoxifen AUC0–24h when tamoxifen was administered with curcumin and piperine, compared to tamoxifen monotherapy.